Company / Operating Cash Flow
10x Genomics, Inc. Operating Cash Flow History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$136.1M
FY2025
5-year range
-$33.6M / $136.1M
FY2021-FY2025
Trend
+1941.6%
vs FY2024
Sector context
#94 of 158
Health Care
What the data says
Operating Cash Flow changed +1942% YoY in FY2025, a notable deviation from the 8-year average annual change of +122%.
Based on SEC 10-K filings.
$136M in FY2025.
Improved from -$15M to $136M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#94 of 158 in Health CareTop 59% of 158This company $136.1M Sector average $1.0B
▼
-86.8% below sector average
Key checks
Key Insights
- 10x Genomics, Inc.'s operating cash flow has grown for 3 consecutive years.
- In FY2025, operating cash flow increased 1941.6% year-over-year.
- Ranks #94 out of 158 companies in the Health Care sector.
- Lowest operating cash flow in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score 0.94 (distress zone, below 1.8 threshold)
- Negative profit margin: -29.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $136.1M | +1941.6% |
| FY2024 | $6.7M | +143.9% |
| FY2023 | -$15.2M | +54.8% |
| FY2022 | -$33.6M | -57.2% |
| FY2021 | -$21.4M | +90.2% |
| FY2020 | -$217.9M | -729.3% |
| FY2019 | $34.6M | +145.3% |
| FY2018 | -$76.4M | -614.2% |
| FY2017 | -$10.7M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026